LISTING OF CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-60 (Canceled)

- 61. (previously presented) A method of ameliorating hepatic steatosis in an animal comprising administering to said animal a therapeutically effective amount of an antisense compound that specifically hybridizes with a nucleic acid molecule encoding apolipoprotein C-III (SEQ ID NO: 4) and inhibits the expression of apolipoprotein C-III so that hepatic steatosis is ameliorated.
- 62. (previously presented) The method of Claim 61, wherein the hepatic steatosis is steatohepatitis.
- 63. (previously presented) The method of Claim 61, wherein the hepatic steatosis is non-alcoholic steatohepatitis.
- 66. 64. (currently amended) The method of Claim 61, wherein said antisense compound comprises an oligonucleotide.
- 67 <u>65.</u> (currently amended) The method of Claim <u>66 64</u>, wherein said oligonucleotide comprises a single-stranded nucleotide.
- 68. 66. (currently amended) The method of Claim 67 65, wherein said oligonucleotide comprises at least one modified internucleoside linkage, sugar moiety, or nucleobase.
- 69. 67. (currently amended) The method of Claim 68 66, wherein said modified internucleoside linkage is a phosphorothioate linkage.
- 70. 68. (currently amended) The method of Claim 68 66, wherein said modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
- 71. 69. (currently amended) The method of Claim 68 66, wherein said modified nucleobase is a 5-methylcytosine.
- 72. 70. (currently amended) A method of lowering liver tissue triglyceride levels in an animal comprising administering to said animal a therapeutically effective amount of an antisense compound that specifically hybridizes with a nucleic acid molecule encoding apolipoprotein C-

- III (SEQ ID NO: 4), wherein said antisense compound inhibits the expression of apolipoprotein C-III and thereby lowers liver tissue triglyceride levels.
- 73. 71. (currently amended) The method of Claim 72 70, wherein said antisense compound comprises an oligonucleotide.
- 74. 72. (currently amended) The method of Claim 73 71, wherein said oligonucleotide comprises a single-stranded nucleotide.
- 75. 73. (currently amended) The method of Claim 74 72, wherein said oligonucleotide comprises at least one modified internucleoside linkage, sugar moiety, or nucleobase.
- 76. 74. (currently amended) The method of Claim 75 73, wherein said modified internucleoside linkage is a phosphorothicate linkage.
- 77. 75. (currently amended) The method of Claim 75 73, wherein said modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
- 78. 76. (currently amended) The method of Claim 75 73, wherein said modified nucleobase is a 5-methylcytosine.
- 79. 77. (currently amended) A method of reducing adipose tissue in an animal comprising administering to said animal a therapeutically effective amount of an antisense compound that specifically hybridizes with a nucleic acid molecule encoding apolipoprotein C-III (SEQ ID NO: 4) wherein said antisense compound inhibits the expression of apolipoprotein C-III and thereby reduces adipose tissue.
- 80. 78. (currently amended) The method of Claim 79 77, wherein said antisense compound comprises an oligonucleotide.
- 81. 79. (currently amended) The method of Claim 80 78, wherein said oligonucleotide comprises a single-stranded nucleotide.
- 82. 80. (currently amended) The method of Claim 81 79, wherein said oligonucleotide comprises at least one modified internucleoside linkage, sugar moiety, or nucleobase.
- 83. 81. (currently amended) The method of Claim 82 80, wherein said modified internucleoside linkage is a phosphorothioate linkage.
- 84. 82. (currently amended) The method of Claim 82 80, wherein said modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

Attorney Docket No.: BIOL0004USA (ISIS.020NP)

85. 83. (currently amended) The method of Claim 82 80, wherein said modified nucleobase is a 5-methylcytosine.